AI
Friday, December 02, 2022 12:20:32 PM
I have a guess as to what Missling will eventually report for the numbers on slide 21 and why they differ from other numbers when he tries to clarify . He seems to want to use the data from subjects who got through the titration phase or completed the study per protocol for the safety data and maybe did the same for clinical endpoints. This is not the ITT population but a common prespecified subgroup analysis (per protocol or protocol completers). ITT is standard. There was some comment by Macfarlane on the video around 1:15 implying that this was the case for the slide 19 analysis. I've never heard anyone use ITT to describe that population. Also no comments about data imputation.
If we do the stats with the numbers on slide 21 and use n=301 and n=161 for the size of the group (n from slides 25, 26 that BTIG confirmed were numbers of protocol completers not the ITT population of everyone who got drug or placebo) then you get 0.049 which could easily spun. I still can't find any way to get 0.033. These 0.025-0.05 results will help to get a new phase 3 rolling and keep the SP above 10, possibly above 14 for a while.
link to Macfarlanes presentation video:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170588463
If we do the stats with the numbers on slide 21 and use n=301 and n=161 for the size of the group (n from slides 25, 26 that BTIG confirmed were numbers of protocol completers not the ITT population of everyone who got drug or placebo) then you get 0.049 which could easily spun. I still can't find any way to get 0.033. These 0.025-0.05 results will help to get a new phase 3 rolling and keep the SP above 10, possibly above 14 for a while.
link to Macfarlanes presentation video:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170588463
